Asthma Therapeutics Market Report by Drug Class, Product Type, Treatment Type, Route of Administration, and Region 2024-2032
천식 치료제 시장 규모는 2023년 180억 달러에 달했습니다. 향후 IMARC 그룹은 시장이 2032년까지 220억 달러에 이를 전망이며, 2024년과 2032년 사이에 1.9%의 복합 연간 성장률(CAGR)을 나타낼 것으로 예측했습니다.
천식 치료제는 천식 치료에 사용되는 다양한 의약품을 의미합니다. 천식은 보통 오염, 알레르기, 먼지와 같은 실내 및 외부 원인 물질로 인해 발생합니다. 이러한 치료제는 일반적으로 기관지 확장제 및 항염증제이며, 코르티코스테로이드, 장시간 작용성 베타작용제(LABA), 메틸크산틴, 면역조절제, 류코트리엔 조절제 등을 포함합니다. 흡입, 주사, 경구 투여가 가능한 많은 병용 요법 약물도 사용됩니다. 이 약은 폐로 통로를 넓히고 공기의 이동을 허용하여 호흡을 향상시킵니다. 또한 폐의 점액을 제거하고 기침하기 쉽게하는 효과도 있습니다.
천식 치료제 시장 동향 :
천식 및 기타 호흡기 질환의 유병률 증가와 진단 기술의 향상은 시장 성장을 가속하는 주요 요인 중 하나입니다. 또한, 효과적인 천식 치료제의 가용성에 대한 대중의 의식 증가도 시장 성장을 뒷받침하고 있습니다. 예를 들어, 천식 환자는 주로 흡입 코르티코스테로이드 약물로 치료되고, 병리학이 진행된 환자 및 지속성 천식 환자는 표적 특이적 약물로 치료됩니다. 또한 면역글로불린 E와 특정 사이토카인을 차단하는 단클론항체(mAbs)에 대한 수요도 확대되고 있습니다. 호흡기 질환 치료를위한 병용 요법의 개발은 또 다른 성장 촉진요인으로 작용합니다. 건강 관리 지출 증가, 의학 분야에서 광범위한 조사 개발(R&D) 활동, 의료 인프라 개선은 시장을 더욱 견인할 것으로 예상되는 기타 요인의 일부입니다.
이 보고서에서 다루는 주요 질문
- 2023년 세계의 천식 치료제 시장 규모는?
- 2024-2032년 세계의 천식 치료제 시장의 예상 성장률은?
- 세계의 천식 치료제 시장을 견인하는 주요 요인은?
- 세계의 천식 치료제 시장에 대한 COVID-19의 영향은?
- 천식 치료제 시장의 약품 클래스별 내역은?
- 세계의 천식 치료제 시장의 제품 유형별 내역은?
- 세계의 천식 치료제 시장의 치료 유형별 내역은?
- 세계의 천식 치료제 시장의 투여 경로별 내역은?
- 천식 치료제 시장의 주요 지역은?
- 세계의 천식 치료제 시장에서 주요 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 천식 치료제 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 약제 클래스별
제7장 시장 내역 : 제품 유형별
- 흡입기
- 시장 동향
- 주요 유형
- 드라이 파우더 흡입기
- 정량 흡입기
- 소프트 미스트 흡입기
- 시장 예측
- 분무기
제8장 시장 내역: 치료 유형별
제9장 시장 분석: 투여경로별
제10장 시장 내역: 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 진입업자의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- AstraZeneca PLC
- Abbott Laboratories
- Amgen Inc.
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Merck Sharp & Dohme Corp.
- Novartis International AG
- Sunovion Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
BJH
The global asthma therapeutics market size reached US$ 18 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 22.0 Billion by 2032, exhibiting a growth rate (CAGR) of 1.9% during 2024-2032.
Asthma therapeutics refer to various pharmaceutical drugs that are used for the treatment of asthma. Asthma is usually triggered by indoor and outdoor causative agents, including pollution, allergens and dust. These therapeutics are usually bronchodilators and anti-inflammatory drugs, which include corticosteroids, long-acting beta-agonists (LABA), methylxanthine, immunomodulators and leukotriene modifiers. A number of combination therapy drugs are also used that can be inhaled, injected, or orally administered. These drugs expand the passageway into the lungs and enable the movement of air to improve breathing. They also aid in clearing mucus from the lungs that gets coughed out with ease.
Asthma Therapeutics Market Trends:
The increasing prevalence of asthma and other respiratory disorders, along with improvements in the diagnostic technologies, is one of the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the availability of effective asthma therapeutics is also providing driving the market growth. For instance, asthmatic patients are primarily treated with inhaled corticosteroids and patients with advanced conditions or persistent asthma are treated with target-specific drugs. There is also an extensive demand for monoclonal antibodies (mAbs) that block immunoglobulin E and specific cytokines. The development of combination therapies for the treatment of respiratory diseases is acting as another growth-inducing factor. Increasing healthcare expenditures, extensive research, and development (R&D) activities in the field of medical sciences and improvements in the healthcare infrastructure are some of the other factors that are expected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global asthma therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug class, product type, treatment type and route of administration.
Breakup by Drug Class:
Anti-Inflammatory Drugs
Bronchodilators
Combination Therapies
Breakup by Product Type:
Inhalers
Dry Powder Inhalers
Metered Dose Inhalers
Soft Mist Inhalers
Nebulizers
Pneumatic Nebulizers
Ultrasonic Nebulizers
Mesh Nebulizers
Breakup by Treatment Type:
Quick-Relief Medications
Long-Term Asthma Control Medications
Breakup by Route of Administration:
Inhalation
Oral
Parenteral
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being AstraZeneca PLC, Abbott Laboratories, Amgen Inc., Biogen Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Novartis International AG, Sunovion Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report
- 1. What was the size of the global asthma therapeutics market in 2023?
- 2. What is the expected growth rate of the global asthma therapeutics market during 2024-2032?
- 3. What are the key factors driving the global asthma therapeutics market?
- 4. What has been the impact of COVID-19 on the global asthma therapeutics market?
- 5. What is the breakup of the global asthma therapeutics market based on the drug class?
- 6. What is the breakup of the global asthma therapeutics market based on the product type?
- 7. What is the breakup of the global asthma therapeutics market based on the treatment type?
- 8. What is the breakup of the global asthma therapeutics market based on the route of administration?
- 9. What are the key regions in the global asthma therapeutics market?
- 10. Who are the key players/companies in the global asthma therapeutics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Asthma Therapeutics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Class
- 6.1 Anti-Inflammatory Drugs
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Bronchodilators
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Combination Therapies
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Product Type
- 7.1 Inhalers
- 7.1.1 Market Trends
- 7.1.2 Major Types
- 7.1.2.1 Dry Powder Inhalers
- 7.1.2.2 Metered Dose Inhalers
- 7.1.2.3 Soft Mist Inhalers
- 7.1.3 Market Forecast
- 7.2 Nebulizers
- 7.2.1 Market Trends
- 7.2.2 Major Types
- 7.2.2.1 Pneumatic Nebulizers
- 7.2.2.2 Ultrasonic Nebulizers
- 7.2.2.3 Mesh Nebulizers
- 7.2.3 Market Forecast
8 Market Breakup by Treatment Type
- 8.1 Quick-Relief Medications
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Long-Term Asthma Control Medications
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Route of Administration
- 9.1 Inhalation
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Oral
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Parenteral
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 AstraZeneca PLC
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Abbott Laboratories
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Amgen Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Biogen Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Boehringer Ingelheim International GmbH
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 F. Hoffmann-La Roche Ltd.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 SWOT Analysis
- 15.3.7 GlaxoSmithKline Plc
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Merck Sharp & Dohme Corp.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Novartis International AG
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sunovion Pharmaceuticals Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 SWOT Analysis
- 15.3.11 Teva Pharmaceutical Industries Ltd.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
